Introduction
In this whitepaper, Partners4Access explores the market access trends that will define 2026, examining how evolving regulatory frameworks, policy reforms, and innovation pressures are reshaping pricing, reimbursement, and launch strategy across Europe and beyond. It offers a forward-looking perspective on how manufacturers, payers, regulators, and patients can navigate an increasingly complex access environment.
Structural change is accelerating across Europe. The implementation of Joint Clinical Assessment (JCA), alongside the EU Pharmaceutical Package, is redefining evidence expectations, incentives, and timelines, while national reforms continue to alter the relative attractiveness of key launch markets.
At the same time, scientific and technological advances are challenging existing access models. Cell and gene therapies are expanding beyond rare diseases, testing the sustainability of traditional pricing and reimbursement approaches, while artificial intelligence is beginning to influence evidence generation, HTA processes, and decision-making bringing both efficiency gains and new demands for transparency.
Patient perspectives are also becoming more prominent, with greater emphasis on real-world outcomes, inclusivity in HTA frameworks, and flexibility in value assessment. Together, these shifts signal a move away from access as a downstream activity toward access as a strategic-design-principle.
2026 represents a critical inflection point. How stakeholders respond to these converging trends will play a decisive role in shaping sustainable access, innovation, and patient outcomes in the years ahead.
Please enter your details in the form on the right to download the full whitepaper
